
Dr. Reddy’s to sell U.S, Canada territory rights of anti-migraine drug
The Hindu
Signs definitive agreement with BioDelivery Sciences International Inc
Dr. Reddy’s Laboratories on Wednesday said it has entered into a definitive agreement to sell its U.S. and Canada territory rights for Elyxyb (celecoxib oral solution) 25 mg/mL to BioDelivery Sciences International Inc (BDSI). Previously known as DFN-15, Elyxyb is indicated for the acute treatment of migraine with or without aura in adults. Under the terms of agreement, Dr. Reddy’s will receive $6 million upfront upon closing followed by $9 million one year from closing. Further, it is eligible to receive event-based, sales-based milestones and quarterly earn-out payments, Dr. Reddy’s said in a release on Wednesday. CEO Erez Israeli said “we are confident in BDSI’s expertise and believe in their ability to realise the full potential of Elyxyb.”More Related News

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












